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Many mutations responsible of Fabry disease destabilize lysosomal alpha-galactosidase, but retain the
enzymatic activity. These mutations are associated to a milder phenotype and are potentially curable
with a pharmacological therapy either with chaperones or with drugs that modulate proteostasis. We
demonstrate the effectiveness of molecular dynamics simulations to correlate the genotype to the
severity of the disease. We studied the relation between protein ﬂexibility and residual enzymatic ac-
tivity of pathological missense mutants in the cell. We found that mutations occurring at ﬂexible sites are
likely to retain activity in vivo. The usefulness of molecular dynamics for diagnostic purposes is not
limited to lysosomal galactosidase because destabilizing mutations are widely encountered in other
proteins, too, and represent a large share of all the ones associated to human diseases.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
For most diseases different types of mutations exist and each
type requires a speciﬁc therapeutic approach. Some mutations
lower the free energy difference between the folded and the
unfolded protein, shifting the equilibrium towards the latter one.
Unstable proteins, although retaining the functional chemical
groups needed for the biological activity, are sensitive to proteolysis
and are cleared by the protein quality control systems in the cell.
Hence, for these mutations, which represent a good share of all the
ones associated with human diseases [1], the reduction of the
protein concentration in the cell is the primary effect and the
reduction of total activity is only a secondary effect. Small chem-
icals, which are known as pharmacological chaperones, bind pref-
erentially to the folded state, thereby at least partially restoring the
equilibrium between folded and unfolded states, and rescue these
mutants [2]. They cannot be used for all the genotypes of a given
disease, but in general are limited to those which retain residual
activity. Nonetheless pharmacological chaperones offer advan-
tages, low cost, oral administration and increased bio-availability.sidase; DGJ, 1-deoxy-gal-
n; RMSF, root mean square
ellis), baaden@smplinux.de
r B.V. This is an open access articlBeside pharmacological chaperones, other small molecules are
being evaluated for therapy. They are not speciﬁc for a given
mutated protein, but alter protein homeostasis [3].
Computational modeling, for instance molecular dynamics
simulations, can be used to predict residual activity in the cell. This
knowledge is important both for diagnosis and for therapy, because
residual activity, the severity of the disease, and responsiveness to
small molecule drugs are correlated.
Fabry disease represents a good example to show how confor-
mational ﬂexibility predictions can be used for designing original
treatments for rare diseases. Among the many computational
techniques that exist to predict protein ﬂexibility such as normal
mode analysis and distance geometry approaches, we will focus on
molecular dynamics (MD). Fabry disease is X-linked and relatively
frequent, 1e9 in 100000 (OMIM: 30150). Different mutations of the
gene encoding lysosomal alpha-galactosidase A (AGAL) result in a
wide phenotypic spectrum, with respect to age at onset, rate of
disease progression, severity of clinical manifestations. Patients
with the late onset or atypical form of Fabry disease retain some
AGAL activity and are asymptomatic until adult age when they
develop cardiac and kidney problems [4].
The treatment of Fabry disease with a pharmacological chap-
erone 1-deoxy-galactonojirimycin (DGJ) was ﬁrst proposed by Fan
et al., in 1999 [5]. The introduction in clinical practice of galactose to
enhance AGAL activity in patients was reported by Frustaci et al., in
2001 [6]. Since then, responsiveness to pharmacological chaper-
ones has been assessed for a huge number of AGAL mutations,e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
M.V. Cubellis et al. / Biochimie 113 (2015) 54e58 55covering both early and late onset forms of Fabry disease (for a
review please consult Fabry_CEP [7] and references therein). A
relatively large proportion of mutants, in particular among muta-
tions associated with the late onset form of Fabry disease, recover
activity when treated with DGJ. In a few cases it was possible to
prove that DGJ acts by enhancing thermodynamic stability of the
mutants [8,9].
In this paper we correlate the ﬂexibility of the sites where AGAL
mutations occur with the residual activity in the cells. This result is
useful for the evaluation of severity and the choice of a personalized
therapy. The direct measure of residual activity in the cells for each
case would be impractical because more than 520 missense/
nonsense mutations have been described in the databank HGMD®
professional [10] for Fabry disease and most of them are private,
that means that they are seen in a single family.
2. Materials and methods
2.1. Molecular dynamics simulations
We used the structure of AGAL solved in the presence (3GXT) or
in the absence (3GXN) of DGJ at pH 4.5 as input. We run a 50 ns MD
simulationwith the amber03 force ﬁeld (a variant of the AMBER-99
one [11]) at the same pH at which crystals were grown.We used the
Yasara program under default conditions combined with fully
automatic optimized assignment of topology and parameters for
the ligand using the AutoSMILES procedure [12,13]. All systems
were solvated with explicit TIP3P water molecules and Naþ and Cl-
counterions were added as background salt and to preserve overall
electrical neutrality. Each system was energy minimized by using
the steepest descent method to relax any steric conﬂicts before
beginning the simulations. Simulations were carried out with pe-
riodic boundary conditions. Long-range electrostatic interactions
were calculated by using PME with a direct-space cut-off of 7.86 Å.
All simulations were performed by using an NVTensemble at 298 K.
A 2 fs/1 fs double-integration time stepwas used. Rootmean square
deviation (RMSD) between structures following least-squares
ﬁtting to the reference energy-minimized input structure, was
calculated with Gromacs [14]. The RMSD value increases steadily in
the ﬁrst 25 ns. After the stabilization of the system, Root mean
square ﬂuctuations (RMSF) of alpha carbons of each residue were
calculated with Gromacs [14].
2.2. Miscellaneous
Graph plotting was carried out with Kaleidagraph (Synergy
Software, PA).
We assigned secondary structure with SEGNO [15]. Active site
residues were identiﬁed with DrosteP [16]. The ﬁgure showing the
AGAL structure colored by RMSF was produced with CHIMERA [17].
3. Results and discussion
3.1. Correlation between alpha-galactosidase ﬂexibility and residual
activity of missense mutants in the cell
An attempt to systematically classify the phenotype of Fabry
disease based on structural features of AGAL was made by Saito
[18]. In this previous work, mutations were divided into two cate-
gories deﬁned as classic or atypical based on clinical signs. We
believe that this classiﬁcation is too simplistic because for most
mutations few affected people are known and symptoms are vari-
able even among patients with the same mutation [19]. In general,
residual enzyme activity is associated with a less severe phenotype
[20,21]. We decided to use a different approach and move frombinary categories to real values, taking advantage of the fact that
enzymatic activity of mutants has been measured in cells derived
from patients or in cells transiently transfected with plasmid car-
rying a speciﬁc AGAL mutation.
We collected data from several laboratories [22e28] and
examined 244 mutations altogether. The effect of mutations de-
pends critically on the positions of the affected residue in the
protein structure and secondarily on the type of substitution,
conservative ones being more tolerated. In a few cases, lack of ac-
tivity can be explained straightforwardly because the mutation
affects the active site or disulphide bridges. We deﬁne active site
residues as those that line themost conserved pocket in the protein
structure: by this deﬁnition the active site residues in AGAL are
W47, D92, D93, Y134, L168, D170, Y207, R227, E203, L206, D231,
S297. When these amino acids are mutated, activity is null or
proximal to zero. Disulphide bridges are essential to maintain the
3D-structure of the protein and it is not surprising that when a
cysteine involved in a bridge (C52, C94; C56, C63; C142, C172; C202,
C223; C378, C383) is mutated, fold, and consequently activity, is
lost. It is worth observing that not all the cysteine residues in AGAL
form disulphide bridges, the exception being C90 and C174.
When the active site is not severely compromised, the activity in
the cells depends on two factors, the speciﬁc activity (U/mg) and
the amount of the mature protein, which in turn depends on sta-
bility. Only in a very few cases it was possible to purify mutants and
measure speciﬁc activity or stability independently, but in these
cases it was shown that most missense mutations observed in
Fabry patients do not affect the maximal velocity (kcat) or the af-
ﬁnity for substrate (KM) [29]. In order to analyze all mutations and
try to correlate their effect in the cell with the position in the
protein structure, we calculated an average residual activity per
site. For example, we assign a value of 10.75% to Q327 because
Q327K and Q327E have 0 or 21.5% residual activity, respectively. We
divided the data in two sets. The ﬁrst one includes 66 sites with
zero average residual activity, the second one 92 sites with non null
average residual activity. This distinction is motivated by the
observation that the residual activity and stability in the cell cor-
relates only for mutants that are not completely inactive.
We carried out MD simulations using the structure of AGAL
solved in the absence (3GXN) or in the presence (3GXT) of DGJ at
pH 4.5 [30] as input. We run a 50 ns simulation at the same pH at
which crystals were grown and calculated root mean square ﬂuc-
tuation (RMSF) values as a measure of ﬂexibility per residue. In
Fig. 1, the structure of AGAL solved in the presence of DGJ (3GXT)
was colored by RMSF with colors ranging from blue (low ﬂexibility)
to white (medium ﬂexibility) to red (high ﬂexibility). AGAL is a
homo-dimer and each subunit is made up by two domains, a TIM
barrel where the active site is located and an antiparallel beta
domain. Inspection of Fig. 1 suggests that ﬂexibility is minimal in
the regions not exposed to solvent buried between subunits, be-
tween domains or inside the TIM barrel.
Indeed accessibility (percent of residue surface exposed to sol-
vent) and ﬂexibility follow the same trend but direct correlation
between the two properties is relatively low, approximately 70%.
In Fig. 2 we show RMSF for themolecular dynamics run reported
on the structurewithout the drug (blue line) or with the drug (black
line).
There is little difference between the two. Notably the region
where the highest difference is observed, spans aa 173e177. This
observation is interesting because Asp 170 makes a salt bridge with
the heterocyclic nitrogen in the drug molecule [30].
The beta strand of the TIM barrel at the tip of which are located
the active site residues, forms the rigid core of the protein. The active
site residues are rigid both in 3GXNand 3GXT. Circles represent sites
wheremutations are associatedwith null residual activity (ﬁrst set).
Fig. 3. Correlation of residual AGAL activity measured in cells with the RMSF per
residue obtained from running molecular dynamics on the 3GXT structure. Flexible
residues that once mutated have activity lower than expected are shown (red circles).
Fig. 1. Crystal structure of AGAL (3GXT) in complex with DGJ (yellow). The structure
was colored by RMSF ranging from blue (low ﬂexibility) to white (medium ﬂexibility)
to red (high ﬂexibility).
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sponding to minima of ﬂexibility or correspond to cysteines
involved in disulphide bond formation (ﬁlled red circles in Fig. 2).
We correlated the residual AGAL activity measured in cells with
the RMSF per residue obtained from running MD simulations on
the substrate-bound 3GXT structure.
As shown in Fig. 3 the correlation is medium (Pearson correla-
tion coefﬁcient R 0.50; p < 0.0001), but the trend is clear. When
looking at this ﬁgure it should be born in mind that the experi-
mental data come from several labs [22e28], who applied different
methods and no attempt was made to exclude a priori those mu-
tants that are known to have reduced kcat or higher KM. Mutations
occurring at ﬂexible sites tend to be less severe. It is interesting to
analyze the outliers, i.e. ﬂexible residues that once mutated, have
lower activity than expected (red in Fig. 3). Most of the outliers are
residues for which abnormal kinetic parameters were determinedFig. 2. RMSF for the molecular dynamics run reported on the structure without the drug
associated with null residual activity, the subset corresponding to cysteines involved in disulp
coil; light gray, helix; dark gray, beta strand.(E59K or R112H) [29], residues lining the active site pocket (Y207)
[31] or intrinsically ﬂexible glycine residues (G35, G183, G258,
G260, G261, G325, G360, G395) which can adopt unusual dihedral
angles. Due to the correlation between ﬂexibility and accessibility,
it is not surprising that mutations occurring at exposed sites tend to
retain residual activity. However it is not possible to ﬁnd a
molecular-level explanation to justify the numerous exceptions
observed among buried as well as exposed sites (data not shown).
We gathered data on the activity of AGAL mutants in cells
treated with DGJ [22e28]. Mutations occurring at the ﬁrst group of
sites, i.e. those with null residual activity, show little, if any,
response to the drug, although exceptions are observed. For all
mutations occurring at the second group of sites, i.e. those retaining
residual activity, exposure to the drug is beneﬁcial. However, the
increase of activity is highly variable and does not correlate with
RMSF (data not shown).(blue line) or with the drug (black line). Circles represent sites where mutations are
hide bonds is ﬁlled in red. Secondary structure is shown as background shading: white,
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dataset for Fabry disease, is easy to generalize for any disease-
related protein with available structural data. MD simulations as
those used in the present study can nowadays almost be setup
automatically and improved computing resources allow a swift
execution of such runs. It remains to be assessed whether simpler
and computationally even less demanding approaches may lead to
correlations of comparable quality.4. Concluding remarks
Fabry disease offers an exquisite example to prove the useful-
ness of chemico-physical methods for medicine. With regard to
diagnosis, we correlated protein ﬂexibility, predicted from MD
simulations on the AGAL protein structure, with the residual ac-
tivity of the pathological mutants measured in cells. Residual ac-
tivity in turn correlates with the severity of the disease [20,21].
With our approach, we tried to overcome and enrich the binary
“disease versus non-disease” classiﬁcation of mutations. Our anal-
ysis reﬂects the spectrum of Fabry disease severity and helps
identifying those patients who are eligible for pharmacological
therapy. People affected by mutations that occur at very ﬂexible
sites should possess a relatively high residual activity and are likely
to develop a mild and late form of the disease, people affected by
mutations occurring at sites of intermediate ﬂexibility should
possess some residual activity and are likely to develop a mild form
of the disease that is responsive to pharmacological chaperones
[23]. People, in particular males, affected bymutations that occur at
rigid sites, or affecting the active site or glycines with positive
dihedral angles should have null residual activity and, conse-
quently, severe and early onset Fabry disease. Nonetheless even in
the less favorable case, somemutationsmight recover activity upon
treatment with pharmacological chaperones [23e28]. The need of a
graduated prediction of disease mutations will be more and more
urgent when exome sequencing becomes largely employed. The
case offered by Fabry disease with more than 400 missense mu-
tations and large phenotypical differences will become common
among genetic diseases. It will not be sufﬁcient to classify a mu-
tation as pathological one, but it will be necessary to predict
whether the symptoms associated to a given genotype are severe,
and which type of therapy is most appropriate.Competing interests
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